Literature DB >> 25139398

Prognostic factors for patients with atypical or malignant meningiomas treated at a single center.

Peng Zhao1, Mengqing Hu, Meng Zhao, Xiaohui Ren, Zhongli Jiang.   

Abstract

The purpose of this study is to summarize our experience in managing patients with an atypical or malignant meningioma at our institution, with a specific focus on determining the prognostic factors for treatment outcome. We reviewed the records of 126 patients with atypical or malignant meningiomas from January 2001 to August 2011. Data collected included gender, age, Karnofsky Performance Scale (KPS) score, pathology results, cleavability, and bone invasion. The symptoms and signs were recorded for further outcome analysis. There were 37 malignant meningiomas and 89 atypical meningiomas. Total resection (Simpson grade I-II) was achieved in 80.9% of atypical patients (n = 72) and 67.6% of malignant patients (n = 25). Forty patients (44.9%) in the atypical group underwent radiotherapy after surgery, while 26 (70.2%) patients underwent radiotherapy in the malignant group. The median follow-up duration was 25 months. Patients with a secondary tumor had a much shorter progression-free survival (PFS) than those with a primary tumor in the malignant group. The malignant meningioma group had lower overall survival. Progression-free survival for patients in the malignant group who received postoperative radiotherapy was longer than that for those who did not receive radiotherapy. In conclusion, total resection of the tumor was important because patients with a secondary tumor were much more likely to have recurrence than patients with a primary tumor in the atypical and malignant meningioma groups. Also, radiotherapy should be performed after surgery for a malignant meningioma.

Entities:  

Mesh:

Year:  2014        PMID: 25139398     DOI: 10.1007/s10143-014-0558-2

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  17 in total

Review 1.  Diagnosis and treatment of atypical and anaplastic meningiomas: a review.

Authors:  Ashok Modha; Philip H Gutin
Journal:  Neurosurgery       Date:  2005-09       Impact factor: 4.654

Review 2.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

3.  Meningioma grading: an analysis of histologic parameters.

Authors:  A Perry; S L Stafford; B W Scheithauer; V J Suman; C M Lohse
Journal:  Am J Surg Pathol       Date:  1997-12       Impact factor: 6.394

4.  Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma.

Authors:  Donald Ming-Tak Ho; Chih-Yi Hsu; Ling-Tan Ting; Hung Chiang
Journal:  Cancer       Date:  2002-03-01       Impact factor: 6.860

5.  Management of atypical and malignant meningiomas: role of high-dose, 3D-conformal radiation therapy.

Authors:  E B Hug; A Devries; A F Thornton; J E Munzenride; F S Pardo; E T Hedley-Whyte; M R Bussiere; R Ojemann
Journal:  J Neurooncol       Date:  2000-06       Impact factor: 4.130

6.  Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases.

Authors:  L Palma; P Celli; C Franco; L Cervoni; G Cantore
Journal:  J Neurosurg       Date:  1997-05       Impact factor: 5.115

7.  Most intracranial meningiomas are not cleavable tumors: anatomic-surgical evidence and angiographic predictibility.

Authors:  M P Sindou; M Alaywan
Journal:  Neurosurgery       Date:  1998-03       Impact factor: 4.654

8.  Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome.

Authors:  J Jääskeläinen; M Haltia; A Servo
Journal:  Surg Neurol       Date:  1986-03

Review 9.  Radiotherapy for atypical or malignant intracranial meningioma.

Authors:  M F Milosevic; P J Frost; N J Laperriere; C S Wong; W J Simpson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-03-01       Impact factor: 7.038

10.  Clinical and radiological features related to the growth potential of meningioma.

Authors:  Hidetoshi Kasuya; Osami Kubo; Masahiko Tanaka; Kosaku Amano; Koichi Kato; Tomokatsu Hori
Journal:  Neurosurg Rev       Date:  2006-09-05       Impact factor: 3.042

View more
  20 in total

1.  Atypical meningioma: progression-free survival in 161 cases treated at our institution with surgery versus surgery and radiotherapy.

Authors:  Waseem Masalha; Dieter Henrik Heiland; Pamela Franco; Daniel Delev; Jan Gerrit Haaker; Oliver Schnell; Christian Scheiwe; Juergen Grauvogel
Journal:  J Neurooncol       Date:  2017-10-28       Impact factor: 4.130

2.  Longitudinal experience with WHO Grade III (anaplastic) meningiomas at a single institution.

Authors:  Suresh K Balasubramanian; Mayur Sharma; Danilo Silva; Vidhya Karivedu; Philipp Schmitt; Glen H Stevens; Gene H Barnett; Richard A Prayson; Paul Elson; John H Suh; Erin S Murphy; Samuel T Chao
Journal:  J Neurooncol       Date:  2016-11-18       Impact factor: 4.130

3.  Clear cell histology portends a worse prognosis than other WHO grade II histologies.

Authors:  Pranay Soni; Jianning Shao; Arbaz Momin; Diana Lopez; Lilyana Angelov; Alireza M Mohammadi; Gene H Barnett; Pablo F Recinos; Varun R Kshettry
Journal:  J Neurooncol       Date:  2021-01-04       Impact factor: 4.130

Review 4.  Meta-analysis of adjuvant radiotherapy for intracranial atypical and malignant meningiomas.

Authors:  Ansley Unterberger; Thien Nguyen; Courtney Duong; Aditya Kondajji; Daniel Kulinich; Isaac Yang
Journal:  J Neurooncol       Date:  2021-02-26       Impact factor: 4.130

5.  Clinical and histopathological predictors of outcome in malignant meningioma.

Authors:  Andrea D Maier; Jiri Bartek; Frank Eriksson; Heidi Ugleholdt; Marianne Juhler; Helle Broholm; Tiit I Mathiesen
Journal:  Neurosurg Rev       Date:  2019-03-13       Impact factor: 3.042

Review 6.  Adjuvant radiotherapy and stereotactic radiosurgery in grade 3 meningiomas - a systematic review and meta-analysis.

Authors:  Amon Bergner; Andrea Daniela Maier; Christian Mirian; Tiit Illimar Mathiesen
Journal:  Neurosurg Rev       Date:  2022-05-11       Impact factor: 2.800

7.  De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors.

Authors:  Matthieu Peyre; Guillaume Gauchotte; Marine Giry; Sébastien Froehlich; Johan Pallud; Thomas Graillon; Franck Bielle; Dominique Cazals-Hatem; Pascale Varlet; Dominique Figarella-Branger; Hugues Loiseau; Michel Kalamarides
Journal:  Neuro Oncol       Date:  2018-07-05       Impact factor: 12.300

8.  High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539.

Authors:  C Leland Rogers; Minhee Won; Michael A Vogelbaum; Arie Perry; Lynn S Ashby; Jignesh M Modi; Anthony M Alleman; James Galvin; Shannon E Fogh; Emad Youssef; Nimisha Deb; Young Kwok; Clifford G Robinson; Hui-Kuo Shu; Barbara J Fisher; Valerie Panet-Raymond; William G McMillan; John F de Groot; Peixin Zhang; Minesh P Mehta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-11-29       Impact factor: 7.038

9.  WHO grade II meningioma: a retrospective study for outcome and prognostic factor assessment.

Authors:  Charles Champeaux; Elena Wilson; Colin Shieff; Akbar Ali Khan; Lewis Thorne
Journal:  J Neurooncol       Date:  2016-06-16       Impact factor: 4.130

10.  Survival benefit of postoperative radiation in papillary meningioma: Analysis of the National Cancer Data Base.

Authors:  Whitney A Sumner; Arya Amini; Todd C Hankinson; Nicholas K Foreman; Laurie E Gaspar; Brian D Kavanagh; Sana D Karam; Chad G Rusthoven; Arthur K Liu
Journal:  Rep Pract Oncol Radiother       Date:  2017-10-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.